SCHEMBL1032800

SCHEMBL1032800

O=C(O)[C@H](CO)Nc1cccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.43
▸ GAA P10253 10/20 0.42
▸ MEN1 O00255 8/20 0.42
▸ KMT2A Q03164 8/20 0.42
▸ HSD17B10 Q99714 8/20 0.42
▸ MAPT P10636 7/20 0.41
▸ HTT P42858 5/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ PKM P14618 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GFER P55789 3/20 0.39
▸ RAB9A P51151 5/20 0.38
▸ LMNA P02545 2/20 0.38
▸ ALOX15 P16050 6/20 0.38
▸ TP53 P04637 4/20 0.38
▸ NPC1 O15118 3/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ POLB P06746 2/20 0.38
▸ USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032798 1.00 CYP2C19 (0.43) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL28071904 0.85 CYP2C19 (0.42) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL5828815 0.85 CYP2C19 (0.42) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL7607064 0.82 MME (0.48) MMEL3MBTL1
SCHEMBL7607068 0.82 MME (0.48) MMEL3MBTL1
SCHEMBL7739887 0.82 NAALAD2 (0.46) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL29159326 0.81 MEN1 (0.45) GAAMEN1KMT2AHSD17B10MAPT
SCHEMBL27548953 0.80 MMP2 (0.42) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL10670688 0.78 GAA (0.47) CYP2C19GAAMEN1KMT2AHSD17B10
SCHEMBL29126042 0.75 CTSK (0.41) CYP2C19GAAMEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117750978-A Synthetic peptide shuttle bioconjugates for intracellular cargo delivery 费尔丹生物公司 2024-03-22 — — CN claimed
CN-116615227-A Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof 费尔丹生物公司 2023-08-18 — — CN claimed
CN-118159298-A Method for producing antibody-linker conjugates 阿拉里斯生物技术股份公司 2024-06-07 — — CN disclosed
CN-117750978-A Synthetic peptide shuttle bioconjugates for intracellular cargo delivery 费尔丹生物公司 2024-03-22 — — CN disclosed
CN-116801910-A Means and methods for producing antibody-linker conjugates 阿拉里斯生物技术股份公司 2023-09-22 — — CN disclosed
CN-116615227-A Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof 费尔丹生物公司 2023-08-18 — — CN disclosed
CN-116406302-A Method of transglutaminase conjugation with amino acid based linkers 阿拉里斯生物技术股份公司 2023-07-07 — — CN disclosed
WO-2023117904-A1 METHOD FOR PEPTIDE SYNTHESIS BACHEM HOLDING AG (CH) 2023-06-29 — — WO disclosed
EP-1301279-B1 ADSORPTION METHOD AND LIGANDS CYTIVA BIOPROCESS R & D AB (SE) 2020-10-28 — — EP disclosed
US-20170172957-A1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN, INC. 2017-06-22 — — US disclosed
EP-2714029-B1 D-SERINE TRANSPORTER INHIBITORS AS PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ALLERGAN INC (US) 2017-04-12 — — EP disclosed
WO-2002013848-A1 HIGHLY HOMOGENEOUS MOLECULAR MARKERS FOR ELECTROPHORESIS INVITROGEN CORPORATION (US) 2002-02-21 — — WO disclosed
WO-2002005959-A2 ADSORPTION METHOD AND LIGANDS AMERSHAM BIOSCIENCES AB (SE) 2002-01-24 — — WO disclosed
WO-2001038227-A2 A METHOD FOR ANION-EXCHANGE ADSORPTION AND ANION-EXCHANGERS AMERSHAM BIOSCIENCES AB (SE) 2001-05-31 — — WO disclosed
WO-2001038228-A1 A METHOD FOR ANION-EXCHANGE ADSORPTION AND THIOETHER ANION-EXCHANGERS AMERSHAM BIOSCIENCES AB (SE) 2001-05-31 — — WO disclosed
EP-1003751-A1 HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS AMGEN INC. (US) 2000-05-31 — — EP disclosed
WO-1999006410-A1 HYDROXAMIC ACID SUBSTITUTED FUSED HETEROCYCLIC METALLOPROTEINASE INHIBITORS AMGEN INC. (US) 1999-02-11 — — WO disclosed
US-5834460-A FOR TREATMENT OF BRAIN OR PSYCHOLOGICAL DISORDERS, ALZHEIMER*S DISEASE, MENTAL RETARDATION OR AUTISM YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1998-11-10 — — US disclosed
CN-1121713-A serine derivatives YAMANOUCHI PHARMA CO LTD (JP) 1996-05-01 — — CN disclosed
EP-0696586-A1 SERINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1996-02-14 — — EP disclosed
Send feedback